Related Experiment Video
Updated: Jun 6, 2026
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
RNA interference as therapeutics for hepatocellular carcinoma
Chuanrui Xu1, Susie A Lee, Xin Chen
1Department of Bioengineering and Therapeutic Science, University of California, San Francisco, CA 94143, USA.
Recent Patents on Anti-Cancer Drug Discovery
|November 30, 2010
Summary
RNA interference (RNAi) offers a promising gene silencing therapy for hepatocellular carcinoma (HCC), a deadly liver cancer. Research focuses on targeting viruses, oncogenes, and tumor growth pathways for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver cancer and a leading cause of cancer-related deaths globally.
- Hepatitis B (HBV) and C (HCV) infections are significant risk factors for HCC development.
- Current HCC treatment options are limited, with poor prognosis for many patients.
Purpose of the Study:
- To review the advancements in RNA interference (RNAi) therapeutics for HCC treatment.
- To discuss potential therapeutic targets for RNAi in HCC, including viral agents and host genes.
- To explore the patent landscape, challenges, and future prospects of RNAi therapy in HCC.
Main Methods:
- Literature review of RNAi applications in HCC research and clinical development.
- Analysis of identified therapeutic targets for RNAi-based gene silencing in HCC.
- Examination of patents related to RNAi therapeutics for liver cancer.
Main Results:
- RNAi technology shows potential for gene silencing in HCC by targeting HBV, HCV, oncogenes, and genes involved in angiogenesis, tumor growth, and metastasis.
- HCC is a suitable model for RNAi therapy development due to efficient delivery into liver tissues.
- Progress has been made in identifying targets and developing RNAi strategies for HCC.
Conclusions:
- RNA interference represents an innovative therapeutic strategy for hepatocellular carcinoma.
- Further research and development are needed to overcome challenges and realize the full potential of RNAi for HCC treatment.
- The development of RNAi therapeutics for HCC is an active area with significant future prospects.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...